# The Efficacy of CAPCT in Patients With PTCL

> **NCT07746245** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 58 (estimated)

## Conditions studied

- Peripheral T-Cell Lymphoma

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Azacitidine (AZA)
- **DRUG:** Prednisone
- **DRUG:** Cyclophosphamide
- **DRUG:** Thalidomide (100mg)

## Key facts

- **NCT ID:** NCT07746245
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07746245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07746245, "The Efficacy of CAPCT in Patients With PTCL". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07746245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*